TPD and Induced Proximity Summit Europe on March 25-27, 2025 in London, United Kingdom

Induced proximity medicines are revolutionising therapeutic strategies, offering groundbreaking solutions for disease treatment.

In 2024 alone, PhoreMost secured $50 million in Series B financing for its degrader programs, while Merck KGaA partnered with C4 Therapeutics in a $756 million deal focused on protein degraders.

However, challenges remain in making PROTACs orally bioavailable, effectively discovering molecular glues, and developing non-degrading proximity therapeutics.

Join the The 5th TPD Summit Europe to network with over 100 experts and learn about the latest advancements in degraders (PROTACs, lysosomal, surface, and ECM), molecular glues, and non-degrading proximity therapeutics. Accelerate your research and bring innovative therapies to patients faster.

URLs:

Tickets: https://go.evvnt.com/2785159-2?pid=10008

Brochure: https://go.evvnt.com/2785159-3?pid=10008

Time: 9:00 AM - 5:00 PM

Prices:

Drug Developer Pricing - Full Access Pass: GBP 3946.00,

Drug Developer Pricing - Conference Only: GBP 2599.00,

Academic and Not-For-Profit Pricing - Full Access Pass: GBP 3246.00,

Academic and Not-For-Profit Pricing - Conference Only: GBP 1699.00,

Service Provider Pricing - Full Access Pass: GBP 5196.00,

Service Provider Pricing - Conference Only: GBP 3099.00

Speakers: Alexandros Patsilinakos, Head of Medicinal Chemistry, Sibylla Biotech, Andrea Testa, Senior Director Discovery Chemistry, Amphista Therapeutics, Andreas Mantoulidis, Research Laboratory Head, Boehringer Ingelheim, Andrew Potterton, Chief Technology Officer, Ternary Therapeutics, Andy Pike, Project leader, DMPK, Oncology R AND D, AstraZeneca, Arnout Schepers, CEO, TenAces Biosciences, Benedict Cross, Chief Technology Officer and Head of Platform, PhoreMost, Chinatsu Sakata-Sakurai, Vice President, Primary Focus Lead, Targeted Protein Degradation, Astellas Pharma, Chris Tame Co-Founder, Chief Executive Officer, Ternary Therapeutics, Gali Prag, Co-Founder, Coltac Therapeutics, Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech, Heide Duevel, PROTAC Technology Platform Lead, Merck Healthcare KGaA, Ian Storer, Head of Hit Discovery, AstraZeneca, Kevin Wilson, Vice President and Head of Chemistry, Foghorn Therapeutics, Kurt Pike, Senior Director - External Innovation, Johnson and Johnson, Luc Brunsveld, Professor, Technical University of Eindhoven and Co-Founder, Ambagon Therapeutics, Luca Naef, Co-Founder and Chief Technology Officer, VantAI, Markus Queisser, Scientific Director, GlaxoSmithKline, Matthias Brand, Chief Scientific Officer, Proxygen, Maureen Galmes-Spit, Vice President - Research, Laigo Bio, Peggy Scherle, Chief Scientific Officer, Prelude Therapeutics​, Randolph Lopez, Co-founder and Chief Technology Officer, A-Alpha Bio Inc., Rick Ewing, Vice President and Head of Chemistry, Rapafusyn Pharmaceuticals, Simon Glerup, Chief Scientific Officer, Draupnir Bio Aps, Vivek Vishnudas, Chief Technology Officer, BPGBio Inc., William Mcewan, Fellow, Cambridge University, Zhangping Xiao, Marie Curie Fellow Postdoc, Tate Group, Imperial College London, Zoran Rankovic Director and Professor - Chemical Biology and Protein Degradation, Institute of Cancer Research